The EAST-AFNET4 trial showed clinical benefit of systematic, early initiation of rhythm control therapy in patients with atrial fibrillation (AF), with 21% fewer cardiovascular events compared to rhythm control given only to symptomatic patients.1 Patients with recently diagnosed AF randomized to rhythm control in the AFFIRM trial did not experience such benefits.2
The EAST-AFNET4 trial showed clinical benefit of systematic, early initiation of rhythm control therapy in patients with atrial fibrillation (AF), with 21% fewer cardiovascular events compared to rhythm control given only to symptomatic patients. This authors reply reviews why now our results with earl control are better then those seen with AFFIRM